IPO for fish oil challenger Omthera
This article was originally published in Scrip
Executive Summary
Omthera Pharmaceuticals has launched on Nasdaq with an IPO worth $64 million. The Princeton, New Jersey firm believes that its fish oil-based pill, Epanova, will become the best-in-class prescription omega-3 product for lowering triglycerides.